DexCom Valuation
| DXCM Stock | USD 89.70 1.05 1.16% |
At this time, the firm appears to be undervalued. DexCom Inc shows a prevailing Real Value of $99.21 per share. The current price of the firm is $89.7. Our model computes the value of DexCom Inc from reviewing the firm fundamentals such as Profit Margin of 0.14 %, shares outstanding of 390.77 M, and Current Valuation of 35.47 B as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting DexCom's valuation include:
Price Book 16.8661 | Enterprise Value | Enterprise Value Ebitda 37.5072 | Price Sales 8.5576 | Forward PE 45.4545 |
Undervalued
Today
Please note that DexCom's price fluctuation is very steady at this time. Calculation of the real value of DexCom Inc is based on 3 months time horizon. Increasing DexCom's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the DexCom stock is determined by what a typical buyer is willing to pay for full or partial control of DexCom Inc. Since DexCom is currently traded on the exchange, buyers and sellers on that exchange determine the market value of DexCom Stock. However, DexCom's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 89.7 | Real 99.21 | Target 96.26 | Hype 90.55 | Naive 92.3 |
The intrinsic value of DexCom's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence DexCom's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of DexCom Inc helps investors to forecast how DexCom stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of DexCom more accurately as focusing exclusively on DexCom's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use DexCom's intrinsic value based on its ongoing forecasts of DexCom's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against DexCom's closest peers.
DexCom Cash |
|
DexCom Valuation Trend
Knowing DexCom's actual value is paramount for traders when making sound investment determinations. Using both DexCom's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
DexCom Total Value Analysis
DexCom Inc is currently forecasted to have valuation of 35.47 B with market capitalization of 34.51 B, debt of 2.53 B, and cash on hands of 2.37 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the DexCom fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
35.47 B | 34.51 B | 2.53 B | 2.37 B |
DexCom Investor Information
About 96.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 1.46. DexCom Inc had not issued any dividends in recent years. The entity had 4:1 split on the 13th of June 2022. DexCom Inc is performing exceptionally good at this time. It has a great probability to report excellent financial results in March.DexCom Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. DexCom has an asset utilization ratio of 62.19 percent. This suggests that the Company is making $0.62 for each dollar of assets. An increasing asset utilization means that DexCom Inc is more efficient with each dollar of assets it utilizes for everyday operations.DexCom Ownership Allocation
DexCom holds a total of 390.77 Million outstanding shares. The majority of DexCom Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in DexCom Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in DexCom. Please pay attention to any change in the institutional holdings of DexCom Inc as this could imply that something significant has changed or is about to change at the company. On January 16, 2025, Representative Kevin Hern of US Congress acquired $50k to $100k worth of DexCom Inc's common stock.DexCom Profitability Analysis
The company reported the previous year's revenue of 4.03 B. Net Income was 576.2 M with profit before overhead, payroll, taxes, and interest of 2.44 B.About DexCom Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of DexCom Inc. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of DexCom Inc based exclusively on its fundamental and basic technical indicators. By analyzing DexCom's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of DexCom's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of DexCom. We calculate exposure to DexCom's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of DexCom's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.5 B | 2.6 B | |
| Pretax Profit Margin | 0.18 | 0.18 | |
| Operating Profit Margin | 0.15 | 0.16 | |
| Net Profit Margin | 0.14 | 0.15 | |
| Gross Profit Margin | 0.61 | 0.64 |
DexCom Growth Indicators
Investing in growth stocks can be very risky. If the company such as DexCom does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 412.7 M | |
| Quarterly Earnings Growth Y O Y | -0.391 | |
| Forward Price Earnings | 45.4545 |
DexCom Current Valuation Indicators
DexCom's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final DexCom's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as DexCom, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use DexCom's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes DexCom's worth.When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.39) | Earnings Share 1.42 | Revenue Per Share | Quarterly Revenue Growth 0.076 | Return On Assets |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.